A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Inclusion Criteria: * adult patients, 18-75 years of age * type 2 diabetes mellitus, treated with stable dose of metformin and sulfonylurea for \>/= 12 weeks prior to screening * HbA1c 7-10% at screening * body weight stable (+/-5%) for \>/= 12 weeks prior to screening * fasting C-peptide \>/=1ng/ml * treatment-naïve for insulin Exclusion Criteria: * diagnosis or history of type 1 diabetes mellitus or secondary forms of diabetes * acute metabolic diabetic complications or evidence of clinically significant diabetic complications * clinically symptomatic gastrointestinal disease * history of chronic pancreatitis or acute idiopathic pancreatitis * \>3 episodes of severe hypoglycemia within 6 months prior to screening * miocardial infarcion, unstable angina pectoris, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within 6 months prior to screening * any treatment with exenatide, exendin analogues, GLP-1 or its analogues